Breaking down the Phase 2 clinical trial data for Retatrutide (LY3437943), the triple GIP/GLP-1/glucagon receptor agonist showing unprecedented weight loss results.
What is Retatrutide?\n\nRetatrutide (LY3437943) is a novel triple-agonist peptide developed by Eli Lilly targeting three receptors simultaneously:\n\n1. GIP receptor (Glucose-dependent insulinotropic polypeptide)\n2. GLP-1 receptor (Glucagon-like peptide-1)\n3. Glucagon receptor\n\n## Phase 2 Trial Results\n\nThe Phase 2 trial (published in NEJM, 2023) enrolled 338 participants with obesity.\n\n### Key Findings\n\n- 24-week results: Up to 17.5% body weight loss\n- 48-week results: Up to 24.2% body weight loss at the 12mg dose\n- Dose-dependent: Higher doses showed greater efficacy\n\n### Dosing Groups\n\n| Dose | 24-Week Loss | 48-Week Loss |\n|------|-------------|-------------|\n| 1mg | -7.2% | -8.7% |\n| 4mg | -12.9% | -17.1% |\n| 8mg | -14.5% | -22.8% |\n| 12mg | -17.5% | -24.2% |\n\n## How It Compares\n\n- Semaglutide (Wegovy): ~15% at 68 weeks\n- Tirzepatide (Mounjaro): ~22.5% at 72 weeks\n- Retatrutide: ~24.2% at just 48 weeks\n\n## Mechanism Advantage\n\nThe triple-agonist approach may explain the superior results:\n\n- GLP-1: Appetite suppression and insulin sensitization\n- GIP: Enhanced incretin effect and fat metabolism\n- Glucagon: Increased energy expenditure and hepatic fat reduction\n\n## Side Effects\n\nMost common adverse events were GI-related:\n- Nausea (most common, typically transient)\n- Diarrhea\n- Vomiting\n- Constipation\n\n## Current Status\n\nRetatrutide is currently in Phase 3 clinical trials. FDA approval is not expected before 2026-2027.\n\n## What This Means for Research\n\nThe triple-agonist approach represents a new frontier in metabolic peptide research, potentially offering superior efficacy compared to dual-agonists like tirzepatide.
Related Articles
New guides, by email
New compound guides and research notes when we publish them. No set schedule. Unsubscribe anytime.
No spam. Unsubscribe anytime.
Founder of BodyHackGuide. Writes the site's guides on peptide research, nootropics and vendor quality, and posts as u/BioChonch on Reddit.

Discussion
Sign in to join the discussion
No comments yet. Be the first to share your thoughts!